MetaCap

IRIDEX (IRIX) vs iTonic (ITOC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IRIDEX (IRIX) has outperformed iTonic (ITOC) over the past year, losing 52.2% versus a loss of 82.0%. iTonic is the larger company by market cap ($11.6 million vs $7.9 million), about 1.5 times the size. IRIDEX converts more of its revenue into profit, with a net margin of -8.4% versus -974.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRIX-52.16%ITOC-81.96%
+75%-8%-91%
Nov 21, 20251 yearNov 20, 2026
IRIX-77.75%ITOC-97.45%
+685%+275%-135%
Sep 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRIX versus ITOC key metrics
MetricIRIXITOC
Share price$0.4449$1.59
Market cap$7.92M$11.63M
1-day change-4.59%+6.00%
YTD return-60.97%-76.40%
1-year return-52.16%-81.96%
5-year return-93.18%—
EPS (TTM)$-0.19$-4.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$52.67M$523.03K
Revenue growth (YoY)+8.23%+16.70%
Net income (latest FY)$-4.44M$-5.10M
Gross margin36.50%62.59%
Operating margin-4.88%-991.71%
Net margin-8.42%-974.68%
52-week high$1.65$18.40
52-week low$0.4296$1.40
Distance from 52-week high-73.04%-91.36%
Analyst consensusnone—
Avg. price target upside+518.12%—
Average volume385.76K42.84K
Shares outstanding17.81M6.84M
Employees937
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRIX has outperformed ITOC by 29.8 percentage points over the past year.
  • IRIDEX is more profitable, keeping -8.4 cents of every revenue dollar as net income versus -974.7 cents for iTonic.
  • iTonic grew revenue faster in its latest fiscal year (+16.70% vs +8.23%).

About IRIDEX

IRIX stock →

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 93 employees

About iTonic

ITOC stock →

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 7 employees

IRIX vs ITOC FAQ

Which is bigger, IRIDEX or iTonic?

iTonic (ITOC) is larger, with a market capitalization of $11.63M compared with $7.92M for IRIDEX (IRIX).

Which stock has performed better over the past year, IRIX or ITOC?

IRIX returned -52.16% over the past 12 months, compared with -81.96% for ITOC (price return, excluding dividends). Past performance does not predict future results.

Are IRIDEX and iTonic in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons